Skip to navigation Skip to content

Participate in a Clinical Trial

Without the participation of people with MS, it would be impossible to develop new and better therapies and other interventions.

Clinical Trials in MS


The latest clinical research in MS, including trials funded by the Society and trials in progressive MS.

Read more

Read more

Posting a Trial

If you would like us to post a study on these pages, please email studies@nmss.org to find out what information you need to submit for review.

Share




Clinical trials help to determine if treatments are safe and effective. Studies are monitored to ensure that the rights and safety of all participants are protected. Make an informed decision before agreeing to participate. Read more in our Guide to Participating in Clinical Trials.

Clinical Trials In Your Area

Interested in clinical trials? Simply search by state, type of MS or keyword and see what’s going on in your area.

  1. Clinical Trial: Plant-Derived Oral Cannabinoid Spray to Treat Muscle Spasticity

    SUMMARY: Investigators are recruiting 446 people with MS worldwide who are being treated for spasticity for a study testing whether adding nabiximols (an oral spray), to ongoing antispasticity therapy can reduce MS-related muscle spasms. The study is sponsored by Jazz Pharmace...
  2. Clinical Trial: Fenebrutinib

    A study to evaluate the effectiveness and safety of fenebrutinib on disability progression and relapse rate. Eligible participants will be randomly assigned to receive either fenebrutinib or teriflunomide. Some may then  receive fenebrutinib during an open label extension.
  3. Clinical Trial: Comparing Experimental Fenebrutinib to Aubagio® in Relapsing MS

     Investigators in the U.S. and abroad are recruiting a total of 1468 people with relapsing forms of MS for two separate studies comparing investigational oral fenebrutinib with Aubagio ® (teriflunomide, Sanofi Genzyme). The studies – also called FENhance – are sponsored by F....
  4. Clinical Trial: Comparing Experimental Fenebrutinib to Ocrevus® in Primary Progressive MS

    Investigators in the U.S. and abroad are recruiting 946 people with primary progressive MS for a study comparing investigational oral fenebrutinib with  Ocrevus ®  (ocrelizumab - Genentech, a member of the Roche Group). The study – also called FENtrepid – is sponsored by F. H...
  5. Clinical Trial: ofatumumab

    A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient- reported outcomes in people with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. FDA Approved medication (Brand na...
  6. Clinical Trial: Behavioral intervention for MS (via Zoom)

    Researchers at Kessler Foundation are studying whether a series of online classes based on cognitive behavioral therapy and positive psychology principles may improve self-efficacy, coping, psychological well-being, and quality of life in multiple sclerosis (MS). Participation...
  7. Clinical Trial: Impact of Vancomycin on the Gut Microbiome and Immune Function in MS

    The goal of this study is to see if changes in the gut microbiome can alter multiple sclerosis outcomes.  Participants are newly diagnosed with MS (symptoms onset lest than 6 months) who have never taken disease-modifying treatment.  Participants will take vancomycin, an antib...
  8. Clinical Trial:IMU-838

    Following a 4-week screening period, participants will take either oral IMU-838 or placebo for a period of 72 weeks during the main period of the study. Participants may need to stop taking certain MS medications during the trial.  An MRI scan will be needed during screening p...
  9. Clinical Trial: Improving New Learning and Memory in MS

    The Kessler Foundation is currently recruiting for a study on memory. Participants will be compensated.. The study involves paper-and-pencil testing and is intended to assess the efficacy of learning and memory techniques within the Multiple Sclerosis population. Additionally,...
  10. Clinical Trial: Ocrelizumab for Preventing MS in Individuals With Radiologically Isolated Disease

    “Radiologically isolated syndrome” (RIS) is diagnosed when it is discovered that someone has brain MRI abnormalities similar in appearance and location to abnormalities seen in people with MS. People with RIS are typically otherwise healthy and without any symptoms common for ...
  11.  |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

Share


The National MS Society is Here to Help

Newly Diagnosed
If you or somone close to you has recently been diagnosed, access our MS information and resources.

Start Here

Start Here
© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.